

## Northern Health Authority Annual Antibigram 2023\*

Greater than or equal to 80% susceptibility = GOOD CHOICE							Less than 80% susceptibility = POOR CHOICE									
Northern Health Authority Gram Negative Organisms % Susceptible	# of isolates	Amoxicillin/ Clavulanate	Ampicillin	Piperacillin/ Tazobactam	Cefazolin	Cefuroxime	Cefixime	Cefotaxime or Ceftriaxone	Ceftazidime	Meropenem	Gentamicin	Tobramycin	TMP/SMX	Ciprofloxacin	Moxifloxacin	Nitrofurantoin <sup>U</sup>
<i>Escherichia coli</i>	4807	85	64	94	88	-	93	94	-	100	95	96	86	82	-	97
<i>Citrobacter freundii</i>	97	R	R	R	R	R	R	R	-	100	97	99	93	90	-	95
<i>Citrobacter koseri</i>	46	26	R	24	24	-	-	26	26	100	100	100	100	100	-	94
<i>Enterobacter cloacae complex<sup>a</sup></i>	275	R	R	-	R	-	-	-	-	100	99	99	95	93	-	30
<i>Klebsiella aerogenes<sup>b</sup></i>	58	R	R	-	R	-	-	-	-	98	100	100	98	97	-	14
<i>Klebsiella oxytoca</i>	162	93	R	97	55	-	96	96	98	99	99	98	92	97	-	88
<i>Klebsiella pneumoniae</i>	498	93	R	95	91	-	95	95	95	100	98	97	93	91	-	43
<i>Morganella morganii</i>	60	R	R	-	R	R	-	-	-	100	88	91	83	82	-	-
<i>Proteus mirabilis</i>	244	93	75	98	74	-	96	97	-	100	96	98	87	94	-	-
<i>Serratia marcescens</i>	46	R	R	-	R	R	-	-	-	100	100	96	100	100	-	R
<i>Pseudomonas aeruginosa</i>	331	R	R	88	-	-	-	R	87	85	97	100	R	85	-	-
<i>Stenotrophomonas maltophilia<sup>c</sup></i>	25	R	R	R	-	-	-	R	R	R	-	-	88	-	-	-
<i>Haemophilus influenzae</i>	60	79	75	-	-	93	-	100	-	-	-	-	56	-	100	-

**Notes** Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

**Legend** a Enterobacter cloacae complex includes Enterobacter asburiae, E. cloacae and E. hormaechei.

b Previously known as Enterobacter aerogenes. Reporting hasn't changed in LIS yet.

c organisms with less than 30 isolates have decreased statistical validity

U Urinary tract infections only

R Intrinsic resistance

- Drug not tested or indicated

10-201-6002 (FF06439-IND-Rev.-03/23)



## Northern Health Authority Annual Antibigram 2023\*

Greater than or equal to 80% susceptibility = GOOD CHOICE							Less than 80% susceptibility = POOR CHOICE									
Northern Health Authority Gram Negative Organisms % Susceptible	# of isolates	Amoxicillin/ Clavulanate	Ampicillin	Piperacillin/ Tazobactam	Cefazolin	Cefuroxime	Cefixime	Cefotaxime or Ceftriaxone	Ceftazidime	Meropenem	Gentamicin	Tobramycin	TMP/SMX	Ciprofloxacin	Moxifloxacin	Nitrofurantoin <sup>U</sup>
<i>Escherichia coli</i>	4807	85	64	94	88	-	93	94	-	100	95	96	86	82	-	97
<i>Citrobacter freundii</i>	97	R	R	R	R	R	R	R	-	100	97	99	93	90	-	95
<i>Citrobacter koseri</i>	46	26	R	24	24	-	-	26	26	100	100	100	100	100	-	94
<i>Enterobacter cloacae complex<sup>a</sup></i>	275	R	R	-	R	-	-	-	-	100	99	99	95	93	-	30
<i>Klebsiella aerogenes<sup>b</sup></i>	58	R	R	-	R	-	-	-	-	98	100	100	98	97	-	14
<i>Klebsiella oxytoca</i>	162	93	R	97	55	-	96	96	98	99	99	98	92	97	-	88
<i>Klebsiella pneumoniae</i>	498	93	R	95	91	-	95	95	95	100	98	97	93	91	-	43
<i>Morganella morganii</i>	60	R	R	-	R	R	-	-	-	100	88	91	83	82	-	-
<i>Proteus mirabilis</i>	244	93	75	98	74	-	96	97	-	100	96	98	87	94	-	-
<i>Serratia marcescens</i>	46	R	R	-	R	R	-	-	-	100	100	96	100	100	-	R
<i>Pseudomonas aeruginosa</i>	331	R	R	88	-	-	-	R	87	85	97	100	R	85	-	-
<i>Stenotrophomonas maltophilia<sup>c</sup></i>	25	R	R	R	-	-	-	R	R	R	-	-	88	-	-	-
<i>Haemophilus influenzae</i>	60	79	75	-	-	93	-	100	-	-	-	-	56	-	100	-

**Notes** Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

**Legend** a Enterobacter cloacae complex includes Enterobacter asburiae, E. cloacae and E. hormaechei.

b Previously known as Enterobacter aerogenes. Reporting hasn't changed in LIS yet.

c organisms with less than 30 isolates have decreased statistical validity

U Urinary tract infections only

R Intrinsic resistance

- Drug not tested or indicated

10-201-6002 (FF06439-IND-Rev.-03/23)



## Northern Health Authority Annual Antibigram 2023\*

Greater than or equal to 80% susceptibility = GOOD CHOICE							Less than 80% susceptibility =POOR CHOICE										
Northern Health Authority  Gram Positive Organisms % Susceptible	# of isolates	Amoxicillin	Ampicillin	Cloxacillin	Penicillin	Cefazolin <sup>A</sup>	Cefotaxime or Ceftriaxone	Erythromycin	Clindamycin	Ciprofloxacin	Moxifloxacin	Gent Synergy	TMP-SMX	Tetracycline	Nitrofurantoin <sup>U</sup>	Vancomycin	Linezolid
<i>Staphylococcus aureus</i> †	2012	-	-	73	-	73	-	73	85	-	-	-	92	97	-	100	-
<i>S. aureus (MRSA)</i> ‡	535	R	R	R	R	R	R	R	83	-	-	-	91	95	-	100	100
<i>Staphylococcus epidermidis</i>	186	-	-	47	-	48	-	42	78	-	-	-	76	89	-	100	-
<i>Staphylococcus lugdunensis</i>	84	-	-	88	-	87	-	100	90	-	-	-	100	99	-	100	100
<i>Enterococcus faecalis</i>	786	100 <sup>B</sup>	100	R	-	-	R	R	R	87	-	87	-	-	99	99	-
<i>Enterococcus faecium</i>	136	R	R	R	-	-	R	R	R	16	-	88	-	-	-	46‡	98
<i>Group A Streptococcus</i>	553	100 <sup>C</sup>	100 <sup>C</sup>	-	100	-	100	79	77	-	-	-	R	-	-	100	-
<i>Group B Streptococcus</i>	189	100 <sup>C</sup>	100	-	99	-	100 <sup>5</sup>	55	56	-	-	-	R	-	-	100	-
<i>Group C &amp; G Streptococcus</i>	230	100 <sup>C</sup>	100 <sup>C</sup>	-	100	-	100 <sup>5</sup>	70	78	-	-	-	R	-	-	100	-
<i>Streptococcus pneumoniae</i>	107	100	-	-	100 <sup>2</sup> 75 <sup>3</sup>	-	100 <sup>2</sup> 91 <sup>3</sup>	72	-	-	100	-	76	-	-	100	-

**Notes** Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.  
Organisms with less than 30 isolates have decreased statistical validity  
MRSA rate = 27%

**Legend** – Drug not tested or indicated  
\$ Insufficient data to provide interpretable susceptibility result  
U U Urinary tract infections only  
R Intrinsic resistance  
A Extrapolated from Cloxacillin  
C Extrapolated from Penicillin

† Total Staphylococcus aureus isolates (includes MSSA and MRSA)  
‡ Represents clinical isolates - excludes colonization/screens  
2 non-meningitis  
3 meningitis  
B Extrapolated from Ampicillin

\*Prepared by Ally King, Microbiology Quality Resource Technologist, January 2023 based on 2022 cumulative AST data from Jan. 1 2022 to Dec. 31 2022,  
As per CLSI document M39-A4 Analysis and presentation of cumulative antimicrobial susceptibility tests data – approved guideline – 4<sup>th</sup> edition

## Northern Health Authority Annual Antibigram 2023\*

Greater than or equal to 80% susceptibility = GOOD CHOICE							Less than 80% susceptibility =POOR CHOICE										
Northern Health Authority  Gram Positive Organisms % Susceptible	# of isolates	Amoxicillin	Ampicillin	Cloxacillin	Penicillin	Cefazolin <sup>A</sup>	Cefotaxime or Ceftriaxone	Erythromycin	Clindamycin	Ciprofloxacin	Moxifloxacin	Gent Synergy	TMP-SMX	Tetracycline	Nitrofurantoin <sup>U</sup>	Vancomycin	Linezolid
<i>Staphylococcus aureus</i> †	2012	-	-	73	-	73	-	73	85	-	-	-	92	97	-	100	-
<i>S. aureus (MRSA)</i> ‡	535	R	R	R	R	R	R	R	83	-	-	-	91	95	-	100	100
<i>Staphylococcus epidermidis</i>	186	-	-	47	-	48	-	42	78	-	-	-	76	89	-	100	-
<i>Staphylococcus lugdunensis</i>	84	-	-	88	-	87	-	100	90	-	-	-	100	99	-	100	100
<i>Enterococcus faecalis</i>	786	100 <sup>B</sup>	100	R	-	-	R	R	R	87	-	87	-	-	99	99	-
<i>Enterococcus faecium</i>	136	R	R	R	-	-	R	R	R	16	-	88	-	-	-	46‡	98
Group A Streptococcus	553	100 <sup>C</sup>	100 <sup>C</sup>	-	100	-	100	79	77	-	-	-	R	-	-	100	-
Group B Streptococcus	189	100 <sup>C</sup>	100	-	99	-	100 <sup>5</sup>	55	56	-	-	-	R	-	-	100	-
Group C & G Streptococcus	230	100 <sup>C</sup>	100 <sup>C</sup>	-	100	-	100 <sup>5</sup>	70	78	-	-	-	R	-	-	100	-
<i>Streptococcus pneumoniae</i>	107	100	-	-	100 <sup>2</sup> 75 <sup>3</sup>	-	100 <sup>2</sup> 91 <sup>3</sup>	72	-	-	100	-	76	-	-	100	-

**Notes** Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.  
Organisms with less than 30 isolates have decreased statistical validity  
MRSA rate = 27%

**Legend** – Drug not tested or indicated  
\$ Insufficient data to provide interpretable susceptibility result  
U U Urinary tract infections only  
R Intrinsic resistance  
A Extrapolated from Cloxacillin  
C Extrapolated from Penicillin

† Total Staphylococcus aureus isolates (includes MSSA and MRSA)  
‡ Represents clinical isolates - excludes colonization/screens  
2 non-meningitis  
3 meningitis  
B Extrapolated from Ampicillin

\*Prepared by Ally King, Microbiology Quality Resource Technologist, January 2023 based on 2022 cumulative AST data from Jan. 1 2022 to Dec. 31 2022,  
As per CLSI document M39-A4 Analysis and presentation of cumulative antimicrobial susceptibility tests data – approved guideline – 4<sup>th</sup> edition